- Home
- CEV vs NTRB Comparison
CEV vs NTRB Comparison
Compare CEV & NTRB Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | CEV | NTRB |
|---|---|---|
| Founded | 1999 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Finance/Investors Services | Industrial Specialties |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 70.8M | 71.7M |
| IPO Year | N/A | N/A |
Fundamental Metrics
Financial Performance| Metric | CEV | NTRB |
|---|---|---|
| Price | $10.40 | $4.50 |
| Analyst Decision | | Buy |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $13.00 |
| AVG Volume (30 Days) | 19.6K | ★ 21.2K |
| Earning Date | 01-01-0001 | 12-03-2025 |
| Dividend Yield | ★ 4.23% | N/A |
| EPS Growth | N/A | N/A |
| EPS | ★ 0.36 | N/A |
| Revenue | N/A | ★ $2,578,059.00 |
| Revenue This Year | N/A | $560.75 |
| Revenue Next Year | N/A | $588.39 |
| P/E Ratio | $29.36 | ★ N/A |
| Revenue Growth | N/A | ★ 42.92 |
| 52 Week Low | $8.83 | $3.72 |
| 52 Week High | $10.91 | $11.78 |
Technical Indicators
Market Signals| Indicator | CEV | NTRB |
|---|---|---|
| Relative Strength Index (RSI) | 52.43 | 28.65 |
| Support Level | $10.33 | $4.59 |
| Resistance Level | $10.62 | $4.99 |
| Average True Range (ATR) | 0.10 | 0.29 |
| MACD | -0.02 | -0.00 |
| Stochastic Oscillator | 31.03 | 12.71 |
Price Performance
Historical ComparisonAbout CEV Eaton Vance California Municipal Income Trust Shares of Beneficial Interest
Eaton Vance CA Muni Income Trust is a non-diversified closed-end investment company. The company's investment objective is to provide current income exempt from regular federal income tax and California state personal income taxes. It invests in municipal obligations, issued by the State of California or its political subdivisions, agencies, authorities and instrumentalities and also has some exposure to corporate bonds.
About NTRB Nutriband Inc.
Nutriband Inc is engaged in the development of a portfolio of transdermal pharmaceutical products. AVERSA technology is the company's product that incorporates aversive agents to prevent the Abuse, Diversion, Misuse, and Accidental exposure of drugs with abuse potential specifically Opioids. The majority of the revenue is generated from the sale of goods that include consumer transdermal and coated products.